By Alan Xu, Product Manager – Analytical Services, Stevanato Group
Selecting the right primary container for an injectable drug product is critical, with the stakes even higher when it comes to complex and sensitive biologics. Underestimating how a new drug will interact with its primary container – or testing it too late – can cause serious delays and expensive corrections. It may even lead to the drug having to be reformulated.
Complex and sensitive biologics require even further consideration as they are prone to react to one or more elements of their primary packaging. Developing and executing a phase-appropriate test plan today increases the chances of creating a more successful world-class product tomorrow. Discover how to identify relevant testing to de-risk your product development – and quickly uncover root causes of product failures.